Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.63 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.52 |
| ▸ | SLC22A12 | Q96S37 | 6/20 | 0.50 |
| ▸ | GRM4 | Q14833 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.42 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.41 |
| ▸ | AR | P10275 | 4/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.40 |
| ▸ | BLM | P54132 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL423366 | 0.98 | IDO1 (0.61) | IDO1TRPV4SLC22A12GRM4KDM4E | |
| SCHEMBL3833327 | 0.84 | SLC22A12 (0.50) | IDO1TRPV4SLC22A12GRM4KDM4E | |
| SCHEMBL6125193 | 0.80 | IDO1 (0.54) | IDO1TRPV4SLC22A12GRM4S1PR3 | |
| SCHEMBL15357415 | 0.78 | IDO1 (0.53) | IDO1TRPV4SLC22A12GRM4S1PR3 | |
| SCHEMBL19557916 | 0.77 | IDO1 (0.51) | IDO1TRPV4SLC22A12GRM4S1PR3 | |
| SCHEMBL16854124 | 0.77 | IDO1 (0.55) | IDO1TRPV4SLC22A12GRM4S1PR3 | |
| SCHEMBL3623834 | 0.76 | TRPV4 (0.52) | IDO1TRPV4CYP11B2 | |
| SCHEMBL12844693 | 0.76 | IDO1 (0.42) | IDO1TRPV4SLC22A12KDM4ENPC1 | |
| SCHEMBL383103 | 0.76 | ABCG2 (0.43) | IDO1TRPV4SLC22A12GRM4KDM4E | |
| SCHEMBL426896 | 0.76 | ABCG2 (0.44) | IDO1SLC22A12KDM4EMAPTS1PR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2937348-B1 | PROCESS FOR THE PREPARATION OF A COMPOUND USED AS MINERALOCORTICOID RECEPTOR ANTAGONIST | KBP BIOSCIENCES PTE LTD (SG) | 2021-09-08 | — | — | EP | claimed |
| US-9809589-B2 | Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor | KBP BIOSCIENCES CO., LTD. (CN) | 2017-11-07 | — | — | US | claimed |
| CN-105026391-B | Crystal formation of compound as mineralocorticoid receptor antagonists and preparation method thereof | 山东亨利医药科技有限责任公司 | 2016-11-16 | — | — | CN | claimed |
| US-20150336950-A1 | CRYSTAL FORM OF COMPOUND USED AS MINERALOCORTICOID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | KBP BIOSCIENCES CO., LTD. (CN) | 2015-11-26 | — | — | US | claimed |
| CN-105026391-A | Crystal form of compound used as mineralocorticoid receptor antagonist and preparation method therefor | KBP BIOSCIENCES CO LTD | 2015-11-04 | — | — | CN | claimed |
| EP-2937348-A1 | CRYSTAL FORM OF COMPOUND USED AS MINERALOCORTICOID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | KBP Biosciences Co., Ltd. (CN) | 2015-10-28 | — | — | EP | claimed |
| CN-113874371-B | Preparation method of tri-fused ring compound and intermediate thereof | 诺和诺德股份有限公司 | 2024-04-16 | — | — | CN | disclosed |
| US-20220144824-A1 | METHOD FOR PREPARING TRICYCLIC COMPOUND, AND INTERMEDIATE THEREOF | NOVO NORDISK A/S (DK) | 2022-05-12 | — | — | US | disclosed |
| US-20220144824-A1 | METHOD FOR PREPARING TRICYCLIC COMPOUND, AND INTERMEDIATE THEREOF | NOVO NORDISK A/S (DK) | 2022-05-12 | — | — | US | disclosed |
| EP-3954688-A1 | CRYSTAL FORMS OF COMPOUND USED AS MINERALOCORTICOID RECEPTOR ANTAGONIST AND METHODS FOR THEIR PREPARATION | KBP BIOSCIENCES PTE. LTD. (SG) | 2022-02-16 | — | — | EP | disclosed |
| EP-3954688-A1 | CRYSTAL FORMS OF COMPOUND USED AS MINERALOCORTICOID RECEPTOR ANTAGONIST AND METHODS FOR THEIR PREPARATION | KBP BIOSCIENCES PTE. LTD. (SG) | 2022-02-16 | — | — | EP | disclosed |
| EP-3932920-A1 | METHOD FOR PREPARING TRICYCLIC COMPOUND, AND INTERMEDIATE THEREOF | KBP Biosciences Co., Ltd. (CN) | 2022-01-05 | — | — | EP | disclosed |
| CN-113874371-A | Preparation method of tricyclic compound and intermediate thereof | 山东亨利医药科技有限责任公司 | 2021-12-31 | — | — | CN | disclosed |
| EP-2089367-A1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | Pfizer Products Incorporated (US) | 2009-08-19 | — | — | EP | disclosed |
| US-20080167294-A1 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER, INC (US) | 2008-07-10 | — | — | US | disclosed |
| US-20080167294-A1 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | PFIZER, INC (US) | 2008-07-10 | — | — | US | disclosed |
| WO-2008053300-A1 | PYRAZOLINE COMPOUNDS AS MINERALOCORTICOID RECEPTOR ANTAGONISTS | PFIZER PRODUCTS INC. (US) | 2008-05-08 | — | — | WO | disclosed |
| EP-1097921-A1 | Phenylhydrazines | SANOFI-SYNTHELABO (FR) | 2001-05-09 | — | — | EP | disclosed |
| EP-0820444-A1 | 1-PHENYLPYRAZOLE-3-CARBOXAMIDES ACTING ON NEUROTENSIN RECEPTORS | SANOFI (FR) | 1998-01-28 | — | — | EP | disclosed |
| WO-1996032382-A1 | 1-PHENYLPYRAZOLE-3-CARBOXAMIDES ACTING ON NEUROTENSIN RECEPTORS | SANOFI (FR) | 1996-10-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220144824-A1 | METHOD FOR PREPARING TRICYCLIC COMPOUND, AND INTERMEDIATE THEREOF | CYP4F3, CYP3A4, CYP4B1 | IDO1 1244/4885TRPV4 3141/4885SLC22A12 4591/4885 |
| US-20150336950-A1 | CRYSTAL FORM OF COMPOUND USED AS MINERALOCORTICOID RECEPTOR ANTAGONIST AND PREPARATION METHOD THEREFOR | NR3C2, REN, MC2R | IDO1 4726/4885TRPV4 634/4885SLC22A12 1285/4885 |
| US-20080167294-A1 | Cardiovascular disorders; liver disorders ; vascular system disorders; antiinflammatory agents; analgesics ; edema; hypotensive agents | REN, F3, EDNRB | IDO1 1563/4885TRPV4 309/4885SLC22A12 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.